Shareable Research Card

ACB - AURORA CANNABIS INC Research And Development Expense

This metric view shows ACB - AURORA CANNABIS INC research and development expense history from SEC company facts.

Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.

Context
Latest reported period: 2024
Latest reported value
CA$3,676,000

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.

Return Loop

Why revisit this metric view

This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.

Latest source-backed update
Latest period end 31 Mar 2025
Why come back
Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
  • Current latest reported period: 2024.
  • Latest reported value on this page: CA$3,676,000.
  • Save this filer if you want to compare the next reported value with this history.

Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.

Latest update

Latest update for Research And Development Expense

New fact period available

Latest reported research and development expense: CA$3,676,000. Open the source-backed page to compare this metric with the newest filing-backed context.

Update date

31 Mar 2025

Page type

Metric history

Latest period

2024

SEC-backed company facts were refreshed from filings filed on 18 Jun 2025.

Benchmark Context

How Research And Development Expense compares with peers

AURORA CANNABIS INC sits in the upper half of the current research and development expense sample.

Compared with

Compared with 44 companies reporting research and development expense in CAD. This keeps the comparison on the same metric and unit family.

Why this is notable

This is about 1.2x the current sample midpoint. Research And Development Expense is up about 2.9% versus the comparable prior period.

  • Visible rows currently span reported period ends from 31 Dec 2016 to 31 Jan 2026.
  • Nearby companies in this sample: ADURO CLEAN TECHNOLOGIES INC. and CENOVUS ENERGY INC..
  • Current sample position: rank #21 of 44 comparable companies.
  • Peer rows use the latest valid value per company for this exact metric and compatible units.

Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Financial Metric Page

AURORA CANNABIS INC: Research And Development Expense

Latest period: 2024. Period end: 31 Mar 2025. Units: CAD. Frequency: annual.

Research And Development Expense is reported in company XBRL facts filed with the SEC.

What This Metric Tells You

  • Shows reported research and development expense over 30 Jun 2018 - 31 Mar 2025.
  • Includes year-over-year change points to highlight acceleration or slowdown.
  • Built from 7 SEC fact rows for this metric and issuer.

How To Read This Chart

  • Start with the latest point, then compare it with the prior periods to see direction.
  • Use annual sequence to compare like-for-like periods.
  • Use YoY change bars to separate growth from contraction across matching periods.

Compare This Metric Across Companies

Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.

AURORA CANNABIS INC appears at rank #21 in the latest comparison sample.

Rank Company Latest value Report period Next step
1 BRP Inc. (doo) CA$434,700,000 Year - 31 Jan 2026 Open BRP Inc. Research And Development Expense
2 CAE INC (cae) CA$123,200,000 Year - 31 Mar 2025 Open CAE INC Research And Development Expense
3 BCE INC (bce) CA$60,000,000 Year - 31 Dec 2025 Open BCE INC Research And Development Expense
4 CYBIN INC. (help) CA$54,910,000 Year - 31 Mar 2025 Open CYBIN INC. Research And Development Expense
5 CAMECO CORP (ccj) CA$38,467,000 Year - 31 Dec 2025 Open CAMECO CORP Research And Development Expense
6 Grace Therapeutics, Inc. (grce) CA$38,366,000 Year - 31 Mar 2019 Open Grace Therapeutics, Inc. Research And Development Expense

Metric Details

Metric identity 1 identity field
Taxonomy
ifrs-full
Metric coverage 3 source fields
Units tracked
CAD
History range
30 Jun 2018 - 31 Mar 2025
Facts on this page
7
Source evidence 1 source field
SEC metric endpoint
Open SEC company concept

Chart Context

Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.

Research And Development Expense, Annual (CAD)
Research And Development Expense, YoY Annual Change (%)

AURORA CANNABIS INC Annual Research And Development Expense (CAD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 CA$3,676,000 +CA$104,000 +2.9% 01 Apr 2024 31 Mar 2025 40-F 18 Jun 2025 2025 FY
2023 CA$3,572,000 -CA$6,817,000 -66% 01 Apr 2023 31 Mar 2024 40-F 18 Jun 2025 2025 FY
2022 CA$10,389,000 -CA$1,058,000 -9.2% 01 Jul 2021 30 Jun 2022 40-F 14 Jun 2023 2022 FY
2021 CA$11,447,000 -CA$14,580,000 -56% 01 Jul 2020 30 Jun 2021 40-F 21 Sep 2022 2022 FY
2020 CA$26,027,000 +CA$11,249,000 +76% 01 Jul 2019 30 Jun 2020 40-F 27 Sep 2021 2021 FY
2019 CA$14,778,000 +CA$13,099,000 +780% 01 Jul 2018 30 Jun 2019 40-F 25 Sep 2020 2020 FY
2018 CA$1,679,000 01 Jul 2017 30 Jun 2018 40-F 11 Sep 2019 2019 FY
* marks a reported value that did not pass the local value check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .